

1 **Generation of Risk Score for Serious Non-Steroidal Anti-** 2 **Inflammatory Drug (NSAID) Induced Cardiovascular Events** 3 **(NAÏVE) among Active-Duty Service Members and Veterans** 4

5 Authors: Timothy J Atkinson, PharmD¹; Justin Petway, PharmD², Whitney Forbes, MS,
6 PhD³; Hannah Thorfinnson, PharmD⁴; Major Ryan C Costantino, MS, PharmD^{3,5}; Laura
7 E Gressler, MS, PhD⁶
8

- 9 1. Pain Management, Opioid Safety, PDMP (PMOP), National Program Office,
10 Department of Veterans Affairs, Washington, DC.
- 11 2. VA Tennessee Valley Healthcare System, Nashville, TN
- 12 3. Enterprise Intelligence and Data Solutions Program Management Office,
13 Program Executive Office, Defense Healthcare Management Systems, Rosslyn,
14 VA, USA.
- 15 4. James A. Haley Veteran's Hospital, Tampa, FL
- 16 5. Department of Military and Emergency Medicine, Uniformed Services University
17 of the Health Sciences, Bethesda, Maryland.
- 18 6. Division of Pharmaceutical Evaluation and Policy, College of Pharmacy,
19 University of Arkansas for Medical Sciences, Little Rock, AR

20
21
22 Word Count: 2884 (max 3000)

23
24 Corresponding Author: Timothy J Atkinson, PharmD; timothy.atkinson@va.gov
25
26

27 **Abstract**

28

29 **Importance:** Cardiovascular disease (CVD) is a major global health concern,
30 responsible for a significant proportion of deaths annually. Despite the widespread use
31 of nonsteroidal anti-inflammatory drugs (NSAIDs) in managing various conditions, their
32 association with cardiovascular events poses a challenge, and existing guidelines lack a
33 reliable risk prediction tool. This study addresses the critical need for an evidence-
34 based instrument to assess the likelihood of NSAID-induced cardiovascular events, that
35 provides clinicians with valuable decision support to improve safety in their use for pain
36 management, especially in patients vulnerable to cardiovascular events.

37 **Objective:** To develop a practical risk scoring tool, NSAID Induced Cardiovascular
38 Events (NAÏVE), for estimating the risk of serious cardiovascular events associated with
39 NSAID use.

40 **Design:** Retrospective nested case-control study

41 **Setting:** The study leveraged data from the DAVINCI database, integrating electronic
42 health records, administrative data, and clinical data from both the Veterans Health
43 Administration (VHA) and the Department of Defense (DoD).

44 **Participants:** The study cohort consisted of individuals with at least one NSAID
45 pharmacy claim, with cases defined as those experiencing non-fatal myocardial
46 infarction, non-fatal stroke, or new heart failure.

47 **Interventions:** Development of the NAÏVE risk scoring tool involved a comprehensive
48 analysis of demographic, clinical, and prescription-related variables, including NSAID
49 exposure, comorbidities, and medication history.

50 **Main Outcomes/Measures:** The primary outcome was the first occurrence of a
51 cardiovascular event.

52 **Results:** The study cohort comprised 231,967 cases and 2,319,670 controls, identified
53 from individuals with at least one NSAID pharmacy claim between October 1, 2016, and
54 September 30, 2020. The risk index, NAÏVE, demonstrated strong discriminatory ability
55 and calibration, with a C-statistic of 0.88. Variables such as age, NSAID exposure,
56 comorbidities, and medication history were associated with increased odds of NSAID-
57 induced cardiovascular events.

58 **Conclusions/Relevance:** NAÏVE is the first evidence-based risk scoring tool providing
59 clinicians with valuable decision support for assessing the potential risk of serious
60 cardiovascular events associated with NSAID use. It fills a crucial gap in clinical
61 practice, allowing for transparent discussions with patients and shared decision-making
62 regarding NSAID prescriptions. Further validation and prospective testing are warranted
63 for broader applicability.

64

65 Word Count: 337 (max 350)

66

67 Introduction

68
69 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide,
70 accounting for 31% of all global deaths or roughly 17.9 million deaths annually. CVD
71 encompasses conditions such as myocardial infarction, stroke, and heart failure.¹
72 Numerous studies have highlighted the prevalence of CVD and its associated risk
73 factors which include hypertension, dyslipidemia, smoking, obesity, diabetes mellitus,
74 sedentary lifestyle, and family history of CVD.²

75
76 Nearly 20 years ago, nonsteroidal anti-inflammatory drugs (NSAIDs) emerged as a
77 threat to provoke cardiovascular events, and yet we still cannot accurately predict the
78 risk of cardiovascular events associated with initiation or continuation of NSAID
79 pharmacotherapy.³⁻⁹ NSAID-related cardiovascular risk has been evaluated in
80 numerous studies with conflicting results mostly focusing on NSAID-specific factors
81 such as COX selectivity, dose-dependent effects, and duration of NSAID therapy.^{5,8,10-13}
82 Unlike other NSAID-related adverse effects such as renal function or GI
83 ulceration/bleeding, previous studies determined that the cardiovascular risks
84 associated with NSAID use do not appear related to dose or duration of treatment.^{13,14}

85
86 Current clinical guidance on NSAID utilization revolves around avoidance of NSAIDs
87 after a cardiovascular event and in certain disease states susceptible to NSAID-related
88 adverse effects.¹⁵⁻¹⁸ However, for more than a hundred years, NSAIDs have been first-
89 line medications for every arthritic and inflammatory condition making them one of the
90 most utilized classes of medications worldwide and a cornerstone of treatment.¹⁹ Today,
91 multiple evidence-based practice guidelines continue to recommend NSAIDs as first-
92 line treatment making avoidance of NSAIDs impractical for many patients.²⁰⁻²⁹ NSAIDs
93 are also important non-opioid pharmacotherapy options and key alternatives to opioid
94 medications for many chronic pain conditions amid the opioid overdose crisis.^{30,31}

95
96 Predictive models and scoring systems (risk indices) that estimate level of risk of an
97 adverse outcome are commonly developed in medical research and clinical practice
98 with the goal of preventing or mitigating an outcome. Common examples include
99 cardiovascular disease² and opioid-induced respiratory depression or overdose.³² While
100 there are screening instruments to assess risk of cardiovascular disease in general, no
101 published instruments currently provide clinically useful, evidence-based risk
102 information about the likelihood of NSAID-induced cardiovascular events.

103
104 This study is a collaboration between clinicians from the Veterans Health Administration
105 (VHA) and Enterprise Intelligence and Data Solutions Program Office of the Defense
106 Healthcare Management Systems in the Department of Defense (DoD). We previously
107 examined the potential predictors of serious NSAID-induced cardiovascular events in a
108 case-control study of US active-duty military and Veterans. Factors with the strongest
109 positive associations included age, NSAID-exposure, previous cardiovascular events,
110 aspirin or other anticoagulants, and specific comorbidities.³³ Based on the results from
111 the previous study, a practical risk scoring tool was developed to estimate the likelihood
112 of nonsteroidal anti-inflammatory drug-induced cardiovascular events (NAÏVE).

113

114 **Methods**

115

116 *Study Design and Data Source*

117

118 A retrospective nested case-control of the DAVINCI (Data Analysis and Visualization
119 Initiative) data was leveraged to develop the risk scores for cardiovascular events.
120 DAVINCI is a collaborative effort between the Department of Defense (DoD) and the
121 Veterans Health Administration (VHA) within the Department of Veterans Affairs (VA) in
122 the US.³⁴ The DAVINCI database integrates and analyzes various types of health data,
123 including electronic health records (EHRs), administrative data, and clinical data from
124 both the DoD and the VA using Observational Medical Outcomes Partnership (OMOP)
125 common data models. The clinical records include information regarding healthcare
126 visits, conditions, dispensed drugs, and procedures in both the inpatient and outpatient
127 settings.

128 *Study Cohort*

129 The study utilized the same derived cohort from the DAVINCI database as a previous
130 study that identified factors associated with the cardiovascular events.³³ More
131 specifically, the study cohort consisted of individuals with at least one NSAID pharmacy
132 claim with a days' supply greater than 7 days between October 1, 2016 and September
133 30, 2020 and excluded individuals under the age of 18, with missing sex, or missing
134 race variables. The authors determined that a 7 days' supply requirement balances
135 competing priorities to remove short-term prescriptions while recognizing that previous
136 studies indicated that CV risk may be significant within the first 30 days. A total of
137 4,408,315 individuals were identified in the dataset with at least one NSAID pharmacy
138 claim. Of these, 231,967 individuals were identified as cases. Cases were defined as
139 individuals who experienced a cardiovascular event. A cardiovascular event included a
140 non-fatal myocardial infarction, non-fatal stroke, and new onset of heart failure and was
141 defined using International Classification of Disease, 10th Revision, Clinical Modification
142 (ICD10-CM) codes. Ten control patients were randomly assigned to each case and
143 assigned the index date of the assigned case.^{35,36} To ensure that included individuals
144 were regular users of TRICARE or VHA health services, individuals were required to
145 have a recorded encounter in the 180 to 365 days prior to their identified or assigned
146 index date. The study cohort consisted of 231,967 cases and 2,319,670 controls.

147 *Covariates and Outcomes*

148 The first occurrence of a cardiovascular event, as defined by ICD-10 codes was the
149 primary outcome of interest. Independent variables considered for the risk score were
150 demographic, clinical, and prescription-related variables. Demographic variables were
151 age, sex, and race. Comorbidity measures included diabetes², hypertension²,
152 dyslipidemia², history of myocardial infarctions¹, arthritis or spondylitis³⁷, peripheral
153 artery disease², chronic kidney disease¹, atherothrombotic disease¹, history of tobacco
154 use², cerebrovascular disease², coronary artery disease², cardiomyopathy¹, obstructive

155 sleep apnea (OSA)¹, liver dysfunction¹, and chronic obstructive pulmonary disease
156 (COPD).¹ Prescription use measures included the use of aspirin and other
157 anticoagulants. NSAID-specific drug information included NSAID selectivity (Cox 1, Cox
158 2, and non-selective),^{5,10,14,38} dosage (low/medium and high dose),^{10,13,14,39} and time
159 since initial exposure (≤ 30 , 31-90, 91+ and no exposure).^{6,13,14,39} Independent variables
160 were collected in the 180 days prior to the index date.

161 *Statistical Analyses*

162 The sample was characterized using descriptive statistics. Continuous variables were
163 summarized using means and interquartile ranges and compared between cases and
164 controls using t-tests. Categorical variables were summarized using frequencies and
165 proportions. Categorical variables between cases and controls were compared using
166 Chi-square tests.

167 Similar to other risk development protocols, multivariable logistic regression was
168 performed to identify potential predictors of cardiovascular events.^{40,41} All independent
169 variables were included in the model. Variables with a p-value greater than 0.10 were
170 removed from the model unless they were statistically identified as confounders.
171 Confounders were determined as variables whose removal from the model led to a 20%
172 or greater change in parameter estimates for one or more of the other variables,
173 compared to the original model. The final model included confounders and all variables
174 with a p-value of 0.10 or less.

175 *Risk Index Construction*

176 The items to be included in the final index were chosen based on the statistical
177 significance of their association with cardiovascular events in the logistic regression
178 model, to strengthen the usability of the risk score and the practical need for a concise
179 instrument that can be easily administered by healthcare professionals. To balance the
180 scientific and statistical considerations of each variable, the following were considered
181 during the risk score item selection process including the strength of association,
182 confirmation of the variable as a risk factor in published literature, generalizability to the
183 population, and the feasibility of obtaining valid and reliable information for each item in
184 the risk score.

185 Point values for each of the risk questionnaire items were calculated by multiplying the β
186 coefficients generated from regression analysis by 10 and rounding to the nearest
187 integer. The calculated risk index scores were used in a multiple logistic regression
188 model to predict probabilities of experiencing the outcome of a cardiovascular event.
189 Receiver operating curves (ROC) and corresponding C-statistics were utilized to
190 determine the model's discrimination ability between individuals with and without the
191 outcome of interest.⁴²

192 To validate the risk index, the generated predicted probabilities were separated into
193 deciles. Ten risk classes were created based on the observed occurrence of
194 cardiovascular events. The number of patients, the average predicted probability of the

195 outcome, and observed incidence of events were calculated for each risk class. All
196 statistical analyses were performed using R. This study followed the Strengthening the
197 Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.⁴³
198 This study was determined to be exempt by the Defense Health Agency Institutional
199 Review Board.

200 <Table 1>

201 Results

202

203 *Descriptive Statistics*

204

205 Baseline characteristics, including demographics (age, race, and sex), predefined risk
206 factors (comorbidities), prescription drug information (including NSAID-related factors),
207 and time since NSAID exposure are shown in Table 1. As described in Forbes et al,
208 unadjusted analyses showed that cases of nonsteroidal anti-inflammatory drug-induced
209 cardiovascular events (NAÏVE) were more likely to be older, non-white or black, male
210 sex, and have a greater burden of illness as indicated by the number of comorbidities.³³
211 Additionally, cases had higher numbers of previous cardiovascular events (history of
212 myocardial infarction and cerebrovascular accidents). Cases were more frequently
213 prescribed other potentially relevant medications including aspirin and anticoagulants
214 than controls. Lastly, low/medium dose NSAIDs were prescribed more in both cases
215 and controls compared to high-dose NSAIDs.

216

217 *Multivariable Modeling*

218

219 The logistic regression model for the primary outcome of NSAID-related composite
220 cardiovascular event of myocardial infarction, nonfatal cerebrovascular accident, and
221 new heart failure resulted in multiple, independent, statistically significant associations.³³
222 Of note, "History of heart failure" was removed from the predefined risk factors as there
223 were only 10 cases of prior heart failure despite the large sample size.

224

225 <Table 2>

226

227 High-dose NSAID use was the only independent variable excluded from multivariable
228 regression modeling due to $P > 0.10$ on bivariate analysis. Demographic variables
229 associated with higher odds of nonsteroidal anti-inflammatory drug-induced
230 cardiovascular events (NAÏVE) included age 45-54 (OR 5.69, 95% CI 5.49, 5.89), 55-64
231 (OR 9.72, 95% CI 9.39, 10.05), 65-74 (OR 12.35, 95% CI 11.94, 12.79), and 75 and
232 older (OR 20.04, 95% CI 19.35, 20.77). Multiple predefined risk factors were
233 associated with an event including: cerebrovascular disease (OR 5.04, CI 95% 4.95,
234 5.13), cardiomyopathy (OR 2.70, 95% CI 2.63, 2.78), history of myocardial infarction
235 (OR 2.07, 95% CI 2.01, 2.13), coronary artery disease (OR 1.77, 95% CI 1.75, 1.80),
236 COPD (OR 1.61, 95% CI 1.59, 1.63), and hypertension (OR 1.57, 95% CI 1.55, 1.59).
237 NSAID exposure was the NSAID-specific risk factor with the strongest association to
238 NAÏVE and the highest likelihood peaking after 31-90 days of exposure (OR 9.54, 95%
239 CI 9.15, 9.96), followed by less than 30 days (OR 8.97, 95% CI 8.58, 9.37), and 91-180

240 days (OR 8.69, 95% CI 8.33, 9.07) with a continued trend of slowly declining risk with
241 longer term exposure. Medication-related risk factors associated with higher odds of the
242 outcome were aspirin (OR 1.71, 95% CI 1.69, 1.73) and other anticoagulants (OR 2.58,
243 95% CI 2.53, 2.62).³³ The odds ratios of secondary outcomes are summarized in
244 Appendix Table 1.

245
246 **<Table 3>**

247 *NAïVE Risk Index Score*

248
249
250 Table 3 shows the risk index items retained from the statistically significant predictors in
251 the final model, and their corresponding assigned point values. Several statistically
252 significant items in the final model were excluded in the final risk score due to lack of
253 clinical significance, and overall impact on model simplicity and accuracy.

254 Demographics excluded from the final risk score were sex and race. Predefined risk
255 factors (comorbidities) excluded were history of heart failure, obstructive sleep apnea
256 (OSA), dyslipidemia, peripheral arterial disease, and arthritis/spondylosis. Excluded
257 NSAID specific factors were COX selectivity and dose.

258
259 Table 4 presents risk classes by deciles of predicted probability of NAïVE and the
260 corresponding observed incidence. Based on risk factors present/absent during the
261 past 12 months before the index date of the NAïVE event, the predicted probability of a
262 cardiovascular event ranged from 3% in the lowest risk class to 93% in the highest, and
263 the observed incidence of NAïVE increased commensurately. The risk class model's C-
264 statistic was 0.88 and Hosmer-Lemeshow goodness-of-fit statistic 1723 (P<0.001),
265 indicating very good calibration and discrimination between patients with and without an
266 event (Table 4).

267
268 **<Table 4>**

270 **Discussion**

271
272 NSAIDs have few alternatives and will continue to be utilized due to the strong body of
273 evidence to support their use for a variety of inflammatory and arthritic conditions
274 including osteoarthritis and low back pain which are among the most common chronic
275 pain conditions where they remain first-line treatment.²⁰⁻²⁶ Healthcare providers are
276 aware of the potentially significant adverse effects with NSAID medications and have
277 strategies around mitigating risks for GI bleeds and monitoring for NSAID-related renal
278 impairment, but not for cardiovascular risk due to an inability to characterize that risk
279 and predict the probability in their patients.⁹ Frontline healthcare providers should have
280 clarity around the level of risk for each of their patients given the widespread nature of
281 NSAID use and the high incidence of cardiovascular events.

282
283 A novel screening tool was developed to estimate the risk of nonsteroidal anti-
284 inflammatory drug-induced cardiovascular events (myocardial infarction, non-fatal
285 stroke, and new heart failure) for patients prescribed oral NSAIDs. The NAïVE risk

286 scoring tool performed well in the VHA/DoD study sample in identifying patients at
287 increased risk of such events. Higher risk scores correlated closely with increased
288 observed occurrence of events. NAÏVE is the first instrument intended to provide
289 healthcare professionals with clinical decision support for assessing the potential for the
290 most serious of adverse effects that can occur in patients being treated for common
291 pain and inflammatory conditions using NSAIDs. It provides current, quantitative,
292 evidence-based information about a patient's level of risk of serious prescription NSAID-
293 induced cardiovascular events. NAÏVE, which is based on a multivariable regression
294 model, integrates independent risk factors and adjusts for confounding influences. As a
295 result, NAÏVE can provide valuable decision support to health care professionals
296 seeking to improve the safe and effective use of NSAIDs for pain management,
297 particularly in complex patients who are biologically vulnerable to cardiovascular events.
298

299 *Intended Use and Interpretation of Results*

300
301 The NAÏVE risk scoring tool requires responding to 13 items divided into 4 sections that
302 include factors well documented in the literature as predictors of cardiovascular events.
303 They comprise the risk factors most strongly associated with NAÏVE including age,
304 NSAID exposure, predefined comorbidities, concomitant prescribed medications, and
305 previous cardiovascular events. The NAÏVE risk scoring tool supports but does not
306 replace the health care provider's judgement in clinical decision-making and provides
307 the basis for transparent conversations and shared decision-making regarding CV risk
308 associated with NSAID use.
309

310 The intent of developing the NAÏVE screening tool is to assist health care professionals
311 who are considering prescribing NSAIDs, to assess a patient's baseline risk or re-
312 evaluate current risk of non-steroidal anti-inflammatory drug-induced cardiovascular
313 events (NAÏVE). Due to its reliance on readily available demographic, medical
314 diagnosis codes, and prescription information in the electronic health record, the NAÏVE
315 screening tool can be easily incorporated into automated clinical decision support tools,
316 dashboards, and artificial intelligence driven health care initiatives for easier adoption
317 and implementation to improve quality of care and efficiency for busy providers. It also
318 can be employed periodically during ongoing treatment to reevaluate risk based on
319 changes in a patient's clinical condition or medication regimen. Explaining a NAÏVE
320 score to a patient creates an opportunity to discuss the benefits and risks associated
321 with the use of NSAIDs. For example, the provider may begin a discussion with,
322 "Patients with risk scores similar to yours (e.g., 61 points) "were predicted to have X%
323 chance (e.g., 26%) "of experiencing a cardiovascular event such as heart attack, stroke,
324 or develop heart failure." "This can occur quickly with the highest risk within the first 90
325 days of treatment. While NSAIDs are first-line treatment and may be effective for your
326 condition, we should consider these potential risks and discuss alternatives."
327

328 *Strengths and Limitations*

329
330 NAÏVE was developed using extensive administrative health care data in the U.S.
331 VHA/DoD population. Limitations inherent to observational studies using administrative

332 data include: 1) medical coding errors/misclassification of comorbidities and previous
333 cardiovascular events; 2) lack of data on patient adherence to prescribed medications
334 or utilization of over-the-counter (OTC) medications including NSAIDs; 3) potentially
335 relevant family history or demographics. In addition, while our VHA/DoD cohort had a
336 significant number of younger patients, women were less represented than the general
337 population and the study sample might not accurately reflect the broader U.S.
338 population of users of prescription NSAIDs. As such, the predictive ability of NAÏVE, like
339 other tools derived from observational data, is subject to residual confounding by
340 currently unknown or excluded contributory factors.

341
342 The final risk index score does not include all known risk factors, such as family history
343 of cardiovascular events. In addition, some variables associated with an event in the
344 VHA/DoD sample were excluded because they were either not clinically significant or
345 did not contribute in a meaningful way to the predicted probability of cardiovascular
346 events and the priority to simplify the model.

347 348 *Implications for Future Research*

349
350 While NAÏVE performed well in the VHA and DoD patient populations, it should be
351 assessed and further validated in a separate population that is more representative of
352 U.S. users of prescription NSAIDs. NAÏVE will also benefit from prospective reliability
353 and validity testing across a broad spectrum of patients. NAÏVE can be formatted for
354 electronic administration via Web or mobile platform to improve its real-world
355 deployment by enabling automated risk scoring, and calculation of risk class.

356 357 **Conclusion**

358
359 NAÏVE is the first-known published risk score to provide current, evidence-based
360 information to health care providers regarding the risk of cardiovascular events with use
361 of prescription NSAIDs. Its performance should be validated, and refined as necessary,
362 in a more generalized patient population or prospectively. Once validated, this index will
363 assist health care professionals in identifying patients who are at increased risk of
364 serious NSAID-induced cardiovascular events and help with decision-making regarding
365 interventions or alternative treatment options to mitigate risk.

366
367

References

1. Benjamin E, Muntner P, Alonso A et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation*. 2019; 139(10):e56-e528. doi: 10.1161/CIR.0000000000000659
2. D'Agostino R, Vasan R, Pencina M et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. *Circulation*. 2008; 117(6):743-753. doi: 10.1161/CIRCULATIONAHA.107.699579
3. Bombardier C, Laine L, Reicin A et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. *N Engl J Med*. 2000; 343:1520-1528. doi: 10.1056/NEJM200011233432103
4. Nussmeier N, Whelton A, Brown M et al. Complications of the Cox-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med*. 2005; **352**:1081-91. doi: 10.1056/NEJMoA050330
5. Kearney P, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. *BMJ*. 2006; 332:1302-1305. doi: 10.1136/bmj.332.7553.1302
6. Ray W, Varas-Lorenzo C, Chung C et al. Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease. *Cir Cardiovasc Qual Outcomes*. 2009; 2:155-163. doi: 10.1161/CIRCOUTCOMES.108.805689
7. Conaghan P. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. *Rheumatol Int*. 2012; 32:1491-1502. doi: 10.1007/s00296-011-2263-6
8. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ*. 2011; 342:c7086. doi: 10.1136/bmj.c7086
9. Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials.
10. Gunter B, Butler K, Wallace R et al. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. *J Clin Pharm Ther*. 2017; 42:27-38. doi: 10.1111/jcpt.12484
11. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. *BMJ*. 2017; 357:j1909. doi: 10.1136/bmj.j1909
12. Martin Arias L, Gonazalez A, Fadrique R et al. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. *J Clin Pharmacol*. 2019; 59(1):55-73. doi: 10.1002/jcph.1302
13. Garcia Rodriguez L, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. *J Am Coll Cardiol*. 2008; 52(20):1628-1636. doi: 10.1016/j.jacc.2008.08.041

14. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. *Eur Heart J*. 2006; 27(14):1657-1663. doi: 10.1093/eurheartj/ehl053
15. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013; 62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019.
16. Page RL, O'Bryant CL, Cheng D et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. *Circulation*. 2016; 134(6):e32-69. doi: 10.1161/CIR.0000000000000426.
17. Whelton PK, Carey RM, Aronow WS et al. 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018; 71(6):1269-1324. doi: 10.1161/HYP.0000000000000066.
18. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med*. 2013;158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040-00007.
19. Ugurlucan M, M Caglar I, N Turnham Caglar F et al. Aspirin: from a Historical Perspective. *Recent Patents on Cardiovascular Drug Discovery*. 2012; 7:71-76. doi: 10.2174/157489012799362377
20. V.A./DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis. Published 2021 [Online]. Available at: <https://www.healthquality.va.gov/guidelines/CD/OA/VADoDOACPG.pdf>. Accessed November 5, 2023.
21. Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis & Cartilage*. 2019; 27:1578-1589. doi: 10.1016/j.joca.2019.06.011.
22. Kolasinski SL, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care & Research*. 2020; 72(2):149-162. doi: 10.1002/acr.24131.
23. VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain. Published 2022 [Online]. Available at: <https://www.healthquality.va.gov/guidelines/pain/lbp/>. Accessed November 5, 2023.
24. Qaseem A, Wilt TJ, McLean RM et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2017; 166(7):514-30. doi: 10.7326/M16-2367
25. Stochkendahl MJ, Kjaer P, Hartvigsen J et al. National clinical guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. *Eur Spine J*. 2018; 27(1):60-75. doi: 10.1007/s00586-017-5099-2

26. Traeger AC, Buchbinder R, Elshaug A et al. Care for low back pain: can health systems deliver? *Bull World Health Organ.* 2019; 97:423-433. doi: 10.2471/BLT.18.226050
27. FitzGerald JD, Dalbeth N, Mikuls T et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Care Res.* 2020; 72(6):744-760. doi: 10.1002/acr.24180
28. Becker CM, Bokor A, Hekinheimo O et al. ESHRE guideline: endometriosis. *Human Reproduction Open.* 2022; 2022(2):1-26. doi: 10.1093/hropen/hoac009
29. Singh JA, Guyatt G, Ogdie A et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis & Rheumatology.* 2019; 71(1):5-32. doi: 10.1002/art.40726
30. VA/DoD Clinical Practice Guideline Use of Opioids in the Management of Chronic Pain. Published 2022 [Online]. Available at: <https://www.healthquality.va.gov/guidelines/pain/cot/>. Accessed November 5, 2023.
31. Dowell D, Ragan KR, Jones CM et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. *MMWR Recomm Repl.* 2022; 71(No. RR-3):1-95. doi: 10.15585/mmwr.rr7103a1
32. Zedler B, Xie L, Wang L et al. Development of a Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Veteran's Health Administration Patients. *Pain Med.* 2015;16(8):1566-1579. doi: 10.1111/pme.12777
33. Forbes W, Petway J, Gressler L et al. Identifying Risk Factors for Cardiovascular Events among Active-Duty Service Members and Veterans Prescribed Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). *J Pain Res.* 2024; 17:1133-1144. doi: 10.2147/JPR.S440802.
34. DuVall SL, Matheny ME, Ibragimov IR, et al. A Tale of Two Databases: The DoD and VA Infrastructure for Clinical Intelligence (DaVINCI). *Stud Health Technol Inform.* 2019;264:1660-1661. doi:10.3233/SHTI190584
35. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. *Am J Epidemiol.* 1992;135(9):1019-1028. doi:10.1093/oxfordjournals.aje.a116396
36. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. II. Types of controls. *Am J Epidemiol.* 1992;135(9):1029-1041. doi:10.1093/oxfordjournals.aje.a116397
37. Wang H, Bail J, He B et al. Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. *Sci Rep.* 2016; 22(6):39672. doi: 10.1038/srep39672
38. Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. *Clin Cardiol.* 2016; 39(2):111-118. doi: 10.1002/clc.22502
39. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Stroke risk and NSAIDs: a systematic review of observational studies. *Pharmacoepidemiol Drug Saf.* 2011;20:1225–1236. Doi: 10.1002/pds.2227

40. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. *Pain Med.* 2014;15(11):1911-1929. doi:10.1111/pme.12480
41. Zedler B, Xie L, Wang L, et al. Development of a Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Veterans' Health Administration Patients. *Pain Med.* 2015;16(8):1566-1579. doi:10.1111/pme.12777
42. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation.* 2007;115(7):928-935. doi:10.1161/CIRCULATIONAHA.106.672402
43. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *International Journal of Surgery.* 2014;12(12):1495-1499. doi:10.1016/j.ijsu.2014.07.013

Table 1 Baseline Demographics & Predefined Risk Factors

| Characteristics | Cases (n = 231,967) n (%) | | Controls (n = 2,319,670) n (%) | | P Value |
|--------------------------------------|---------------------------------|------|--------------------------------------|-------|---------|
| DEMOGRAPHICS | | | | | |
| Age (years), median (IQR) | 69 | 14 | 49 | 32 | <0.001 |
| Age Group (years) | | | | | <0.001 |
| 18-34 | 3971 | 1.71 | 673864 | 29 | |
| 35-44 | 6444 | 2.78 | 346182 | 14.9 | |
| 45-54 | 18485 | 7.97 | 334967 | 14.4 | |
| 55-64 | 54305 | 23.4 | 404898 | 17.5 | |
| 65-74 | 89380 | 38.5 | 414475 | 17.9 | |
| 75+ | 59382 | 25.6 | 145284 | 6.26 | |
| Male | 216417 | 93.3 | 1916362 | 82.6 | <0.001 |
| Race | | | | | <0.001 |
| Black or African American | 47039 | 20.3 | 500047 | 21.6 | |
| White | 145523 | 62.7 | 1553051 | 67 | |
| Other | 39405 | 17 | 266572 | 11.5 | |
| PREDEFINED RISK FACTORS | | | | | |
| Diabetes | 96042 | 41.4 | 359266 | 15.5 | <0.001 |
| Hypertension | 181387 | 78.2 | 829599 | 35.8 | <0.001 |
| Dyslipidemia | 148788 | 64.1 | 773176 | 33.3 | <0.001 |
| History of Myocardial Infarction | 13314 | 5.74 | 14497 | 0.625 | <0.001 |
| Arthritis or Spondylitis | 6887 | 2.96 | 31240 | 1.35 | <0.001 |
| Peripheral Arterial Disease | 21595 | 9.31 | 38968 | 1.68 | <0.001 |
| Chronic Kidney Disease | 29643 | 12.8 | 64783 | 2.79 | <0.001 |
| Atherothrombotic Disease | 10885 | 4.69 | 20250 | 0.873 | <0.001 |
| History of Tobacco Use (Dx Only) | 34515 | 14.9 | 190430 | 8.21 | <0.001 |
| Cerebrovascular Disease | 41791 | 18 | 38342 | 1.65 | <0.001 |
| Coronary Artery Disease | 69186 | 29.8 | 126074 | 5.43 | <0.001 |
| Cardiomyopathy | 16127 | 6.95 | 17439 | 0.752 | <0.001 |
| Aspirin Use | 69054 | 29.8 | 170292 | 7.34 | <0.001 |
| Other Anticoagulant Use | 38386 | 16.5 | 52462 | 2.26 | <0.001 |
| Obstructive Sleep Apnea | 56751 | 24.5 | 357819 | 15.4 | <0.001 |
| Liver Dysfunction | 7497 | 3.23 | 26553 | 1.14 | <0.001 |
| COPD | 50860 | 21.9 | 119186 | 5.14 | <0.001 |
| PRESCRIPTION DRUG INFORMATION | | | | | |
| BY ACTIVE INGREDIENT | | | | | |
| Celecoxib | 17587 | 7.58 | 106505 | 4.59 | <0.001 |

| | | | | | |
|------------------------------------|--------|--------|---------|---------|---------|
| Diclofenac | 19681 | 8.48 | 124792 | 5.38 | <0.001 |
| Diflunisal | 101 | 0.0435 | 369 | 0.0159 | <0.001 |
| Etodolac | 6841 | 2.95 | 39324 | 1.7 | <0.001 |
| Fenoprofen | 80 | 0.0345 | 349 | 0.015 | <0.001 |
| Flurbiprofen | 60 | 0.0259 | 230 | 0.00992 | <0.001 |
| Ibuprofen | 69068 | 29.8 | 815442 | 35.2 | <0.001 |
| Indomethacin | 10302 | 4.44 | 49567 | 2.14 | <0.001 |
| Ketoprofen | 37 | 0.016 | 181 | 0.0078 | <0.001 |
| Ketorolac | 198 | 0.0854 | 1181 | 0.0509 | <0.001 |
| Mefenamic Acid | 3 | 0.0013 | 88 | 0.00379 | 0.08179 |
| Meloxicam | 62405 | 26.9 | 392807 | 16.9 | <0.001 |
| Nabumetone | 1543 | 0.665 | 7784 | 0.336 | <0.001 |
| Naproxen | 53190 | 22.9 | 496578 | 21.4 | <0.001 |
| Piroxicam | 526 | 0.227 | 4170 | 0.18 | <0.001 |
| Sulindac | 2451 | 1.06 | 11862 | 0.511 | <0.001 |
| Other (Summation of Highlighted) | 2540 | 1.09 | 14312 | 0.617 | <0.001 |
| BY SELECTIVITY | | | | | |
| COX 1 | 82151 | 35.4 | 878473 | 37.9 | <0.001 |
| COX 2 | 86072 | 37.1 | 532371 | 23 | <0.001 |
| Non-Selective | 71888 | 31 | 614930 | 26.5 | <0.001 |
| BY DOSE CATEGORY | | | | | |
| Low/Medium Dose | 189875 | 81.9 | 1656424 | 71.4 | <0.001 |
| High Dose | 44190 | 19.1 | 300509 | 13 | <0.001 |
| TIME SINCE INITIAL EXPOSURE (DAYS) | | | | | <0.001 |
| LEQ 30 | 15630 | 6.74 | 136896 | 5.9 | |
| 31-90 | 33182 | 14.3 | 260316 | 11.2 | |
| 91-180 | 38287 | 16.5 | 319594 | 13.8 | |
| 181-365 | 52383 | 22.6 | 466322 | 20.1 | |
| 366-730 | 54133 | 23.3 | 459522 | 19.8 | |
| 731+ | 32563 | 14 | 257109 | 11.1 | |
| No Exposure | 5789 | 2.5 | 419911 | 18.1 | |

Table 2 Primary Outcome: Composite Cardiovascular Events

| Covariates | All Patients | | | |
|---------------------|--|--------|--|---------|
| | (Cases, n = 231,967; Controls, n = 2,319,670) | | | |
| | Odds Ratio | 95% CI | | P Value |
| DEMOGRAPHICS | | | | |
| Age Group (years) | | | | |

| | | | | |
|---|-------|-------|-------|--------|
| 18-34 (reference) | | | | |
| 35-44 | 2.59 | 2.49 | 2.70 | <0.001 |
| 45-54 | 5.69 | 5.49 | 5.89 | <0.001 |
| 55-64 | 9.72 | 9.39 | 10.05 | <0.001 |
| 65-74 | 12.35 | 11.94 | 12.79 | <0.001 |
| 75+ | 20.04 | 19.35 | 20.77 | <0.001 |
| Male | 1.18 | 1.16 | 1.20 | <0.001 |
| Race | | | | |
| Black or African American | 1.08 | 1.07 | 1.10 | <0.001 |
| Other | 1.13 | 1.12 | 1.15 | <0.001 |
| White (reference) | | | | |
| PREDEFINED RISK FACTORS | | | | |
| Diabetes | 1.33 | 1.32 | 1.35 | <0.001 |
| Hypertension | 1.57 | 1.55 | 1.59 | <0.001 |
| Dyslipidemia | 0.91 | 0.90 | 0.92 | <0.001 |
| History of Myocardial Infarction | 2.07 | 2.01 | 2.13 | <0.001 |
| Arthritis or Spondylitis | 1.22 | 1.19 | 1.26 | <0.001 |
| Peripheral Arterial Disease | 1.23 | 1.21 | 1.26 | <0.001 |
| Chronic Kidney Disease | 1.42 | 1.39 | 1.44 | <0.001 |
| Atherothrombotic Disease | 1.55 | 1.51 | 1.60 | <0.001 |
| History of Tobacco Use (Dx Only) | 1.37 | 1.35 | 1.39 | <0.001 |
| Cerebrovascular Disease | 5.04 | 4.95 | 5.13 | <0.001 |
| Coronary Artery Disease | 1.77 | 1.75 | 1.80 | <0.001 |
| Cardiomyopathy | 2.70 | 2.63 | 2.78 | <0.001 |
| Aspirin Use | 1.71 | 1.69 | 1.73 | <0.001 |
| Other Anticoagulant Use | 2.58 | 2.53 | 2.62 | <0.001 |
| Obstructive Sleep Apnea | 1.06 | 1.05 | 1.07 | <0.001 |
| Liver Dysfunction | 1.40 | 1.36 | 1.44 | <0.001 |
| COPD | 1.61 | 1.59 | 1.63 | <0.001 |
| PRESCRIPTION DRUG INFORMATION | | | | |
| BY SELECTIVITY | | | | |
| COX 1 | 1.03 | 1.00 | 1.05 | 0.0291 |
| COX 2 | 1.09 | 1.06 | 1.11 | <0.001 |
| Non-Selective | 1.08 | 1.05 | 1.10 | <0.001 |
| BY DOSE CATEGORY | | | | |
| Low/Medium Dose | 1.06 | 1.02 | 1.10 | 0.0014 |
| High Dose | 1.02 | 0.98 | 1.05 | 0.3619 |
| TIME SINCE INITIAL EXPOSURE (DAYS) | | | | |
| No Exposure (reference) | | | | |
| LEQ 30 | 8.97 | 8.58 | 9.37 | <0.001 |

| | | | | |
|---------|------|------|------|--------|
| 31-90 | 9.54 | 9.15 | 9.96 | <0.001 |
| 91-180 | 8.69 | 8.33 | 9.07 | <0.001 |
| 181-365 | 8.02 | 7.69 | 8.37 | <0.001 |
| 366-730 | 7.14 | 6.85 | 7.45 | <0.001 |
| 731+ | 5.80 | 5.55 | 6.06 | <0.001 |

Table 3. Risk Score Calculation

| Question | Points for Yes Response |
|----------------------------|-------------------------|
| Patient's age group | |
| 35 – 44 | 9 |
| 45 – 54 | 17 |
| 55 – 64 | 23 |
| 65 – 74 | 25 |
| 75+ | 30 |

| In the past year, has the patient had a healthcare visit (outpatient, inpatient, or ED) involving any of the following health conditions? | |
|--|----|
| Diabetes | 3 |
| Hypertension | 5 |
| Myocardial infarction | 7 |
| Chronic kidney disease | 3 |
| Atherothrombotic disease | 4 |
| History of tobacco use | 3 |
| Cerebrovascular disease | 16 |
| Coronary artery disease | 6 |
| Cardiomyopathy | 10 |
| Liver dysfunction | 3 |
| COPD | 5 |
| Other medications | |
| Aspirin | 5 |
| Other anticoagulant | 9 |
| Time since initial NSAID exposure (Prescription \geq7 days and no gaps >30 days) | |
| 30 days or fewer | 22 |
| 31 – 90 days | 23 |
| 91 days or more | 21 |

Table 4. Risk Classes and Predicted Probabilities of NSAID-Induced Cardiovascular Events

| Risk Class | Risk Index Score (Points) | All Patients (n=2551637), n(%)* | Average Predicted Probability (95%CI) | Observed Incidence |
|-------------------|----------------------------------|--|--|---------------------------|
| 1 | 0-50 | 1,811,997 (71.0) | 0.03 (0.03, 0.03) | 0.02 |
| 2 | 51-58 | 409,312 (16.0) | 0.14 (0.14, 0.14) | 0.14 |
| 3 | 59-63 | 137,973 (5.4) | 0.24 (0.24, 0.24) | 0.26 |
| 4 | 64-68 | 77,499 (3.0) | 0.34 (0.34, 0.34) | 0.39 |
| 5 | 69-72 | 37,932 (1.5) | 0.46 (0.46, 0.46) | 0.49 |
| 6 | 73-76 | 27,188 (1.1) | 0.55 (0.55, 0.55) | 0.55 |

| | | | | |
|----|-------|--------------|-------------------|------|
| 7 | 77-80 | 18,131 (0.7) | 0.65 (0.65, 0.65) | 0.60 |
| 8 | 81-85 | 15,088 (0.6) | 0.74 (0.74, 0.74) | 0.64 |
| 9 | 86-93 | 11,443 (0.4) | 0.84 (0.83, 0.84) | 0.69 |
| 10 | >=94 | 5,074 (0.2) | 0.93 (0.93, 0.93) | 0.75 |

*Percentage total not equal to 100 due to rounding

Model Performance

C-Statistic=0.88